Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

GlobeNewswire July 8, 2020

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Business Wire July 8, 2020

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Business Wire June 22, 2020

Xencor to Present at Upcoming Investor Conferences

Business Wire May 26, 2020

Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Business Wire May 15, 2020

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

Business Wire May 13, 2020

Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Business Wire May 13, 2020

Xencor Reports First Quarter 2020 Financial Results

Business Wire May 7, 2020

Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020

Business Wire April 30, 2020

Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend(TM) XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19

Business Wire March 25, 2020

Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

Business Wire February 24, 2020

Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020

Business Wire February 18, 2020

Xencor to Present at Upcoming Investor Conferences

Business Wire February 6, 2020

Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

Business Wire February 5, 2020

Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

Business Wire January 8, 2020

Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

Business Wire December 20, 2019

Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

Business Wire December 18, 2019

Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

Business Wire December 9, 2019

Xencor to Present at Upcoming Investor Conferences

Business Wire November 13, 2019

Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting

Business Wire November 6, 2019